Company news

Zentalis Pharmaceuticals, Inc. news in 2025

Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

November 10, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 3, 2025

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

November 3, 2025

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2025

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

August 26, 2025

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

August 6, 2025

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

April 28, 2025

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

April 23, 2025

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

March 26, 2025

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

March 25, 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

March 15, 2025

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

March 3, 2025

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

January 27, 2025

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

January 8, 2025

Decks in 2025